SCHEMBL3080940

SCHEMBL3080940

CC(C)Cn1c(=O)n(C)c(=O)c2c(Nc3ccccc3)n[nH]c21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 9/20 0.44
PDE1B Q01064 9/20 0.44
PDE1C Q14123 9/20 0.44
PDE2A O00408 7/20 0.44
LMNA P02545 3/20 0.43
PKM P14618 1/20 0.43
PDE5A O76074 4/20 0.39
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CCND2 P30279 1/20 0.39
CCND3 P30281 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CFTR P13569 1/20 0.39
TSHR P16473 1/20 0.39
PDE4A P27815 1/20 0.39
MAPK1 P28482 1/20 0.39
ADORA1 P30542 1/20 0.39
SCN1A P35498 1/20 0.39
PDE6C P51160 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1652844 0.80 XDH (0.48) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL2873217 0.79 ALDH1A1 (0.45) LMNAPKMTSHRMAPK1SMN1; SMN2
SCHEMBL2863823 0.69 PKM (0.47) LMNAPKMCYP1A2CYP3A4ADORA1
SCHEMBL2837094 0.69 BRD4 (0.40) LMNACYP1A2CYP3A4HTTGAA
SCHEMBL9608334 0.68 PDE1B (0.52) PDE1APDE1BPDE1CPDE2ASMN1; SMN2
SCHEMBL194641 0.67 PDE1B (0.73) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL2454720 0.67 PDE1B (0.50) PDE1APDE1BPDE1CPDE2ALMNA
SCHEMBL3666558 0.66 PDE1B (0.72) PDE1APDE1BPDE1CPDE2ALMNA
SCHEMBL3081044 0.66 PDE1B (0.57) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL3091517 0.66 PDE1B (0.72) PDE1APDE1BPDE1CPDE2APDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240028-B1 Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical INTRA CELLULAR THERAPIES INC (US) 2016-07-20 EP disclosed
US-20150197524-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-07-16 US disclosed
US-8846693-B2 Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones INTRA-CELLULAR THERAPIES, INC. (US) 2014-09-30 US disclosed
US-20100273753-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2010-10-28 US disclosed
EP-2240028-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2010-10-20 EP disclosed
WO-2009073210-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273753-A1 ORGANIC COMPOUNDS OPRD1, PGR, HTR1D PDE1A 102/4885PDE1B 147/4885PDE1C 234/4885
US-20150197524-A1 ORGANIC COMPOUNDS OPRD1, HTR1D, DRD1 PDE1A 77/4885PDE1B 115/4885PDE1C 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.